Significant Response to Camrelizumab Plus Targeted Drugs in Recurrent Intrahepatic Cholangiocarcinoma: a Case Report and Literature Review

Abstract

Purpose Intrahepatic cholangiocarcinoma is the second most common primary liver cancer, and is associated with a poor prognosis and rising incidence rate. Methods Here, we reported the case of a middle-aged Asian male who presented with a 9.5-cm liver lesion and was diagnosed with intrahepatic cholangiocarcinoma. Results The patient experienced recurrence three times, twice following radical resection and standard adjuvant chemotherapy and once following camrelizumab plus apatinib, after which the tumor progressed with elevated CA 19.9 level. After tissue biopsy for next-generation sequencing, apatinib was replaced by lenvatinib, and the patient achieved disease control again, with a progression-free survival of 10 months. Conclusion Combined immunotherapy and targeted therapy regimens are a promising approach for refractory intrahepatic cholangiocarcinoma. Further well-designed prospective clinical trials are needed to confirm the efficacy and safety. Since intrahepatic cholangiocarcinoma is characterized by high heterogeneity and with complex crosstalk among oncogenic pathways, further exploration is required to more deeply understand the mechanism of action of this treatment approach and guide individualized treatment selection.

Hepatic cavernous hemangioma developed in non-small cell lung cancer patients after receiving Camrelizumab treatment: two case reports

“…This has resulted, it was found that Camrelizumab can bind highly specifically to the C, C’, and FG ends of the PD-1 molecule, enabling it to exhibit high affinity and occupancy for the PD-1 receptor. This allows Camrelizumab to more effectively block the PD-1/PD-L1 pathway and promote the release of IFNγ by T cells ( 26 ). Camrelizumab exhibits potent anti-tumor activity with an IC50 of 0.7 nmol/L and an EC50 of 0.38 nnmol/L when binding to PD-1.Tislelizumab, another PD-1 inhibitor approved by the CFDA, is widely used in the treatment of common malignancies.…”